Our Global Biologics CDMO Manufacturing Network

The global Just – Evotec Biologics network includes two US-based and one EU-based site, offering biotherapeutics discovery, cell line, analytical, process development capabilities as well as early clinical to commercial cGMP biomanufacturing.

Furthermore, we can leverage the whole Evotec network globally to support integrated or complementary antibody/biologics activities and benefit from therapeutic area experts’ input.

The J.POD facility design and our standardized platform are enabling us to seamlessly transfer work around the globe... We can be manufacturing late-phase clinical material at our J.POD in the US, and then quickly transfer that process for commercialization to the J.POD facility in France.
Kevin Ingham, Manufacturing Operations and Site Head, Redmond, US

Safe Supply Chain Network

Establishing our facilities in geopolitical stable regions is another contributor to our value proposition. 

We want to be close to our partners, offering stable and efficient supply chains. Additionally, we comply with local regulations to meet your quality standards and access US and EU networks and expertise.

Need to secure flexible and low COGS commercial supply chain in a specific geography?

We offer access to commercial capacity within our J.POD facilities network but can also enable strategic Biopharma partners with dedicated J.POD facilities leveraging our proprietary continuous manufacturing technology platform.

As part of our mission to expand global access to patients, we are also ready to enable fast J.POD deployment to face pandemics and explore such strategies with governments and non-profit organizations.

Philip Boehme

Philip Boehme

EVP Partnering & Transformation

Logo Just white
Just – Evotec Biologics is a mission-driven Business Unit of Evotec with the aim of radically improving access to biologics through a de-risked, agile approach, coupled with significantly lower manufacturing cost. Over the years we have advanced an industry-transforming bioprocessing platform, which we leverage with our partners to drive what we call the paradigm shift in biologics.